These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35290837)

  • 1. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis.
    Abufarhaneh M; Pandya RK; Alkhaja A; Iansavichene A; Welch S; Lazo-Langner A
    Thromb Res; 2022 May; 213():47-56. PubMed ID: 35290837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.
    Lee YG; Kim I; Lee E; Bang SM; Kang CH; Kim YT; Kim HJ; Wu HG; Kim YW; Kim TM; Lee KW; Lee SH; Kim DW; Heo DS
    Thromb Haemost; 2014 Jun; 111(6):1112-20. PubMed ID: 24477503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.
    Dou F; Li H; Zhu M; Liang L; Zhang Y; Yi J; Zhang Y
    Respir Res; 2018 May; 19(1):88. PubMed ID: 29743116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.
    Dou F; Zhang Y; Yi J; Zhu M; Zhang S; Zhang D; Zhang Y
    Thromb Res; 2020 Feb; 186():36-41. PubMed ID: 31864154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
    Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
    Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
    Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study.
    Lin M; Lu Y; Yu Q; Chen Z; Peng J; Cai X
    Lung Cancer; 2022 Oct; 172():29-34. PubMed ID: 35986977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
    Lee B; Lee T; Lee SH; Choi YL; Han J
    Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
    Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
    Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
    Han C; Zou H; Ma J; Zhou Y; Zhao J
    Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
    Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
    Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
    Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.